Tolmar, Inc., a specialty pharmaceutical company, has officially opened its new Northern Illinois Laboratory at Rosalind Franklin University’s Innovation and Research Park (IRP) in North Chicago, Illinois. This facility enhances Tolmar’s capacity to develop and commercialize pharmaceutical products while strengthening the university’s ecosystem of industry innovation.
Founded in 2007, Tolmar is recognized globally for its expertise in long-acting injectable drug delivery systems. The company specializes in creating and manufacturing products in areas such as urology, oncology, and endocrinology. Notably, its leading product treats advanced prostate cancer and is available in 89 countries worldwide.
Expanding Research and Development Capabilities
The new laboratory at Rosalind Franklin’s IRP will work in tandem with Tolmar’s existing team in Colorado, enhancing the company’s research and development capabilities. This strategic move not only boosts Tolmar’s innovation efforts but also increases its regional footprint, which already includes executive offices and sales teams located in Buffalo Grove, Illinois.
Dr. Dave Loffredo, Tolmar’s Vice President of Innovation, expressed enthusiasm about the new facility. “Tolmar is excited to expand our development capability, now covering both Colorado and Illinois,” he stated. “After an exhaustive search, we found a great home at Rosalind Franklin’s IRP. Tolmar scientists are eager to be a part of this dynamic research environment and hope to grow our presence at IRP.”
Dr. Stace Porter, Senior Vice President of Development Operations at Tolmar, highlighted the advantages of the new laboratory. “At Rosalind Franklin University’s Innovation and Research Park, Tolmar gains world-class research space and the chance to collaborate with leading scientists and advanced research cores,” he said. “Surrounded by Lake County’s vibrant network of global life science companies, we’re excited to grow and innovate here.”
A Hub for Biomedical Innovation
Rosalind Franklin University’s IRP is a state-of-the-art facility that spans 100,000 square feet and houses six research centers, including the Center for Cancer Cell Biology, Immunology and Infection. The university is known for its commitment to excellence in research across various disciplines, including neuroscience, diabetes, and inherited disorders.
Dr. Joseph DiMario, Executive Vice President for Research at RFU, welcomed Tolmar to the university’s innovation ecosystem. “We look forward to collaborations that can help accelerate new product development,” Dr. DiMario commented. “The IRP provides an environment that fosters the kind of intellectual biomedical ‘collisions’ that drive meaningful innovation.”
This collaboration between Tolmar and Rosalind Franklin University underscores the growing synergy between academia and industry, fostering advancements that could lead to significant breakthroughs in pharmaceutical development.
For further information about Tolmar, visit their official website at www.tolmar.com. To learn more about Rosalind Franklin University, go to rosalindfranklin.edu.
